These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22974232)

  • 1. Hepatocyte growth factor in the neighborhood reverses resistance to BRAF inhibitor in melanoma.
    Nickoloff BJ; Vande Woude G
    Pigment Cell Melanoma Res; 2012 Nov; 25(6):758-61. PubMed ID: 22974232
    [No Abstract]   [Full Text] [Related]  

  • 2. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF, a target in melanoma: implications for solid tumor drug development.
    Flaherty KT; McArthur G
    Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting BRAF in melanoma: biological and clinical challenges.
    Mandalà M; Voit C
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
    Straussman R; Morikawa T; Shee K; Barzily-Rokni M; Qian ZR; Du J; Davis A; Mongare MM; Gould J; Frederick DT; Cooper ZA; Chapman PB; Solit DB; Ribas A; Lo RS; Flaherty KT; Ogino S; Wargo JA; Golub TR
    Nature; 2012 Jul; 487(7408):500-4. PubMed ID: 22763439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF in melanoma: current strategies and future directions.
    Salama AK; Flaherty KT
    Clin Cancer Res; 2013 Aug; 19(16):4326-34. PubMed ID: 23770823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors.
    Lai F; Jin L; Gallagher S; Mijatov B; Zhang XD; Hersey P
    Adv Pharmacol; 2012; 65():27-43. PubMed ID: 22959022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promising Strategies for Overcoming BRAF Inhibitor Resistance Based on Known Resistance Mechanisms.
    Li QS; Shen BN; Xu HJ; Ruan BF
    Anticancer Agents Med Chem; 2020; 20(12):1415-1430. PubMed ID: 32321411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications.
    Haluska F; Pemberton T; Ibrahim N; Kalinsky K
    Semin Oncol; 2007 Dec; 34(6):546-54. PubMed ID: 18083378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On or off target: mutations, models, and predictions.
    Garraway LA; Hahn WC
    Sci Transl Med; 2010 Jun; 2(35):35ps28. PubMed ID: 20538617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma.
    Hüser L; Sachindra S; Granados K; Federico A; Larribère L; Novak D; Umansky V; Altevogt P; Utikal J
    Int J Cancer; 2018 Dec; 143(12):3131-3142. PubMed ID: 29905375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The new arms race against melanoma.
    Lejeune FJ
    Melanoma Res; 2006 Feb; 16(1):1-2. PubMed ID: 16432449
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.
    Rossi A; Roberto M; Panebianco M; Botticelli A; Mazzuca F; Marchetti P
    Eur J Pharmacol; 2019 Nov; 862():172621. PubMed ID: 31446019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HGF-cMET signaling pathway in conferring stromal-induced BRAF-inhibitor resistance in melanoma.
    Filitis DC; Rauh J; Mahalingam M
    Melanoma Res; 2015 Dec; 25(6):470-8. PubMed ID: 26317169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma.
    Verduzco D; Flaherty KT; Smalley KS
    Exp Dermatol; 2015 Sep; 24(9):657-8. PubMed ID: 26010519
    [No Abstract]   [Full Text] [Related]  

  • 16. Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma.
    Cohen JV; Sullivan RJ
    Clin Cancer Res; 2019 Oct; 25(19):5735-5742. PubMed ID: 30992297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor.
    Curry JL; Falchook GS; Hwu WJ; Torres-Cabala CA; Duvic M; Tetzlaff MT; Prieto VG
    Am J Dermatopathol; 2013 Feb; 35(1):125-8. PubMed ID: 22878367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microenvironment-mediated resistance to anticancer therapies.
    Olson OC; Joyce JA
    Cell Res; 2013 Feb; 23(2):179-81. PubMed ID: 22945358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards a unified model of RAF inhibitor resistance.
    Solit DB; Rosen N
    Cancer Discov; 2014 Jan; 4(1):27-30. PubMed ID: 24402945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma.
    Lo RS; Shi H
    Methods Mol Biol; 2014; 1102():163-74. PubMed ID: 24258979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.